Skip to main content

Table 5 Glomerular and tubular histological characteristics after ex vivo pravastatin pre-treatment

From: Ex vivo exposure of bone marrow from chronic kidney disease donor rats to pravastatin limits renal damage in recipient rats with chronic kidney disease

  Healthy + DMEM BMC recipients ( n = 5) Healthy + pravastatin BMC recipients ( n = 5) CKD + DMEM BMC recipients ( n = 10) CKD + pravastatin BMC recipients ( n = 9)
Glomerular     
 CD3 0.68 ± 0.34 0.72 ± 0.33 0.76 ± 0.19 0.67 ± 0.27
 ED-1 7.4 ± 1.0 5.0 ± 2.9 10.5 ± 5.5 7.9 ± 1.9
 Ki67 8.0 ± 0.76 6.4 ± 1.7 7.8 ± 1.8 7.8 ± 2.3
 TUNEL 2.6 ± 1.3 2.1 ± 1.3 7.0 ± 4.6 4.4 ± 3.7
 γH2AX 1.5 ± 1.6 0.6 ± 0.4 1.2 ± 0.8 1.4 ± 0.8
 GFP+ 7.0 ± 6.6 2.5 ± 0.7 2.3 ± 1.9 5.2 ± 2.9
 JG12 42.5 ± 10 44.4 ± 9.9 42.8 ± 12.5 48.1 ± 9.0
Tubular     
 CD3 81 ± 11 96 ± 45 122 ± 59 98 ± 27
 TUNEL 35 ± 24 65 ± 59 147 ± 116 95 ± 79
 γH2AX 5.0 ± 1.6 4.3 ± 2.0 6.1 ± 2.8 5.3 ± 1.5
 GFP+ 83 ± 82 31 ± 24 23 ± 20 50 ± 38
  1. Data presented as mean ± standard deviation per 50 glomeruli or 20 tubular fields. BMC, bone marrow cell; CKD, chronic kidney disease; DMEM, Dulbecco’s modified Eagle medium; GFP, green fluorescent protein; TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling.